BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9299938)

  • 1. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays.
    Junker R; Brandt B; Zechel C; Assmann G
    Clin Chem; 1997 Sep; 43(9):1588-94. PubMed ID: 9299938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls.
    Oberpenning F; Weining C; Brandt B; De Angelis G; Heinecke A; Hamm M; Stieber P; Hertle L; Schmid HP; Semjonow A
    Eur Urol; 2002 Dec; 42(6):577-82; discussion 582. PubMed ID: 12477653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
    Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
    Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
    Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
    Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
    Maeda H; Arai Y; Okubo K; Aoki Y; Okada T; Maekawa S
    Int J Urol; 1998 Jul; 5(4):343-8. PubMed ID: 9712442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
    Ohuchi H; Mikata K; Miyoshi Y; Ohta J; Osada Y; Uemura H; Yao M; Takeda M; Noguchi S; Kubota Y; Hosaka M; Jinza S; Asakura T; Ebato T
    Nihon Hinyokika Gakkai Zasshi; 2000 Dec; 91(12):695-9. PubMed ID: 11201129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free and total PSA in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
    Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
    Patel D; White PA; Milford Ward A
    BJU Int; 2000 Apr; 85(6):686-9. PubMed ID: 10759666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
    Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
    Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.